Scholarlink

<p>Precision-guided therapy (PGT) approaches have shown improved survival in children with high-risk cancer, but it is unclear whether children with H3K27-altered diffuse midline glioma (DMG) benefit from this approach. Here we report on the cohort of patients with DMG who were consecutively enroled in the Australian Childhood Cancer PRecISion Medicine for Children with Cancer (PRSIM) clinical trial (NCT03336931), a prospective cohort study aimed at providing PGT recommendations based on comprehensive molecular profiling. A total of 68 patients with DMG were enroled and 58 (85%) had WGS and RNAseq performed. PGT was recommended for 50 patients (74%). Eighteen patients (26%), who received 21 PGTs, were eligible for survival analysis. The overall response rate (CR or PR) was 48% (<i>n</i> = 10). Median overall survival for the PGT group was 21.3 months versus 12.1 months for those that did not receive PGT (<i>p</i> = 0.34). Patients who received PGT after tumor progression had significantly improved overall survival (<i>p</i> = 0.007) and subsequent progression-free survival (<i>p</i> = 0.001) compared to those that received unguided therapy or reirradiation alone. These results highlight the feasibility of a precision-guided approach and demonstrate its potential clinical benefit in patients with DMG.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Precision-guided therapy in H3K27-altered diffuse midline glioma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月19日

查看全文
  • Campbell J. L. McKay,
  • Chelsea Mayoh,
  • Phoebe Power,
  • Sophie Jessop,
  • Shampavi Sriharan,
  • Jordan Staunton,
  • Sarah Trinder,
  • Nataliya Zhukova,
  • Cristina Mignone,
  • Dinisha Govender,
  • Frank Alvaro,
  • Peter Downie,
  • Jordan R. Hansford,
  • Tim Hassall,
  • Santosh Valvi,
  • Marion K. Mateos,
  • Paulette Barahona,
  • Andrew J. Gifford,
  • Gabor Tax,
  • Maria Tsoli,
  • Emmy M. Dolman,
  • Marie Wong,
  • Mark Cowley,
  • Glenn M. Marshall,
  • Toby N. Trahair,
  • Paul G. Ekert,
  • Michelle Haber,
  • Vanessa Tyrell,
  • Loretta M. S. Lau,
  • Neevika Manoharan,
  • David S. Ziegler,
  • Dong-Anh Khuong-Quang

摘要

Precision-guided therapy (PGT) approaches have shown improved survival in children with high-risk cancer, but it is unclear whether children with H3K27-altered diffuse midline glioma (DMG) benefit from this approach. Here we report on the cohort of patients with DMG who were consecutively enroled in the Australian Childhood Cancer PRecISion Medicine for Children with Cancer (PRSIM) clinical trial (NCT03336931), a prospective cohort study aimed at providing PGT recommendations based on comprehensive molecular profiling. A total of 68 patients with DMG were enroled and 58 (85%) had WGS and RNAseq performed. PGT was recommended for 50 patients (74%). Eighteen patients (26%), who received 21 PGTs, were eligible for survival analysis. The overall response rate (CR or PR) was 48% (n = 10). Median overall survival for the PGT group was 21.3 months versus 12.1 months for those that did not receive PGT (p = 0.34). Patients who received PGT after tumor progression had significantly improved overall survival (p = 0.007) and subsequent progression-free survival (p = 0.001) compared to those that received unguided therapy or reirradiation alone. These results highlight the feasibility of a precision-guided approach and demonstrate its potential clinical benefit in patients with DMG.